BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

24398

544210

EMCURE

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

EMCURE PHARMACEUTICALS L performance

Today’s low

Today’s high

₹ 1000.40 ₹ 1048.50
₹ 1021.90

52 week low

52 week high

₹ 889.00 ₹ 1580.00
₹ 1021.90

Open Price

₹ 1018.90

Prev. Close

₹ 1009.10

Volume (Shares)

52010.00

Total traded value

₹ 531.49

Upper Circuit

₹ 1110.00

Lower Circuit

₹ 908.20

info

EMCURE PHARMACEUTICALS L Share Price Update

As of the latest trading session, EMCURE PHARMACEUTICALS L share price is currently at ₹ 1021.9, which is up by ₹ 12.80 from its previous closing. Today, the stock has fluctuated between ₹ 1000.40 and ₹ 1048.50. Over the past year, EMCURE PHARMACEUTICALS L has achieved a return of -24.81 %. In the last month alone, the return has been -5.03 %. Read More...

EMCURE PHARMACEUTICALS L fundamentals


  • Market cap (Cr)

    18,511.93

  • P/E Ratio (TTM)

    93.74

  • Beta

    1.32

  • Book Value / share

    149.27

  • Return on equity

    8.52%

  • EPS (TTM)

    11.30

  • Dividend yield

    0.19%

  • Net profit/quarter (Cr)

    50.20

info icon alternate text
  • Market cap (Cr)

    18,513.75

  • P/E Ratio (TTM)

    93.74

  • Beta

    1.26

  • Book Value / share

    149.27

  • Return on equity

    8.52%

  • EPS (TTM)

    11.30

  • Dividend yield

    0.19%

  • Net profit/quarter (Cr)

    50.20

info icon alternate text

EMCURE PHARMACEUTICALS L Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 1028.81
Operating Expense 988.08
Net Profit 50.20
Net Profit Margin (%) 4.87
Earnings Per Share (EPS) 2.65
EBITDA 143.83
Effective Tax Rate (%) 25.35
Particulars SEP 2024 (Values in Cr)
Revenue 1104.63
Operating Expense 1040.21
Net Profit 86.92
Net Profit Margin (%) 7.86
Earnings Per Share (EPS) 4.62
EBITDA 207.10
Effective Tax Rate (%) 27.17
Particulars JUN 2024 (Values in Cr)
Revenue 970.29
Operating Expense 947.75
Net Profit 40.45
Net Profit Margin (%) 4.16
Earnings Per Share (EPS) 2.23
EBITDA 147.70
Effective Tax Rate (%) 26.52
Particulars MAR 2024 (Values in Cr)
Revenue 902.55
Operating Expense 891.91
Net Profit 28.98
Net Profit Margin (%) 3.21
Earnings Per Share (EPS) 1.60
EBITDA 131.15
Effective Tax Rate (%) 18.32
Particulars DEC 2023 (Values in Cr)
Revenue 870.16
Operating Expense 842.03
Net Profit 48.26
Net Profit Margin (%) 5.54
Earnings Per Share (EPS) 3.78
EBITDA 157.00
Effective Tax Rate (%) 20.41
Particulars MAR 2024 (Values in Cr)
Revenue 3497.66
Operating Expense 3426.68
Net Profit 160.83
Net Profit Margin (%) 4.59
Earnings Per Share (EPS) 8.89
EBITDA 570.83
Effective Tax Rate (%) 19.54
Particulars MAR 2023 (Values in Cr)
Revenue 3107.09
Operating Expense 3013.95
Net Profit 160.06
Net Profit Margin (%) 5.15
Earnings Per Share (EPS) 9.07
EBITDA 557.69
Effective Tax Rate (%) 24.62
Particulars MAR 2022 (Values in Cr)
Revenue 3387.24
Operating Expense 2903.50
Net Profit 446.81
Net Profit Margin (%) 13.19
Earnings Per Share (EPS) 24.66
EBITDA 927.34
Effective Tax Rate (%) 27.51
Particulars MAR 2021 (Values in Cr)
Revenue 3153.66
Operating Expense 2689.83
Net Profit 420.48
Net Profit Margin (%) 13.33
Earnings Per Share (EPS) 23.25
EBITDA 837.03
Effective Tax Rate (%) 24.57
Particulars MAR 2020 (Values in Cr)
Revenue 2375.71
Operating Expense 2244.48
Net Profit 175.21
Net Profit Margin (%) 7.37
Earnings Per Share (EPS) 9.69
EBITDA 516.87
Effective Tax Rate (%) 22.02
Particulars MAR 2024 (Values in Cr)
Book Value / Share 162.97
ROE % 19.35
ROCE % 18.23
Total Debt to Total Equity 0.86
EBITDA Margin 19.18
Particulars MAR 2023 (Values in Cr)
Book Value / Share 138.30
ROE % 25.03
ROCE % 20.75
Total Debt to Total Equity 1.01
EBITDA Margin 20.40
Particulars MAR 2022 (Values in Cr)
Book Value / Share 109.90
ROE % 32.98
ROCE % 25.00
Total Debt to Total Equity 1.06
EBITDA Margin 23.80
Particulars MAR 2021 (Values in Cr)
Book Value / Share 125.68
ROE % 20.14
ROCE % 21.08
Total Debt to Total Equity 1.11
EBITDA Margin 24.83
Particulars MAR 2020 (Values in Cr)
Book Value / Share 105.72
ROE % 9.43
ROCE % 10.41
Total Debt to Total Equity 1.19
EBITDA Margin 15.66
Particulars MAR 2024 (Values in Cr)
Book Value / Share 106.82
ROE % 8.52
ROCE % 10.08
Total Debt to Total Equity 0.89
EBITDA Margin 16.32
Particulars MAR 2023 (Values in Cr)
Book Value / Share 101.84
ROE % 9.01
ROCE % 10.69
Total Debt to Total Equity 0.94
EBITDA Margin 17.95
Particulars MAR 2022 (Values in Cr)
Book Value / Share 94.69
ROE % 22.26
ROCE % 20.50
Total Debt to Total Equity 0.79
EBITDA Margin 27.38
Particulars MAR 2021 (Values in Cr)
Book Value / Share 127.27
ROE % 19.95
ROCE % 18.77
Total Debt to Total Equity 0.68
EBITDA Margin 26.72
Particulars MAR 2020 (Values in Cr)
Book Value / Share 105.86
ROE % 11.26
ROCE % 13.14
Total Debt to Total Equity 0.67
EBITDA Margin 23.79
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 232.40
Total Assets 7806.16
Total Liabilities 7806.16
Total Equity 3121.76
Share Outstanding 181152116
Price to Book Ratio 0.00
Return on Assets (%) 6.38
Return on Capital (%) 9.56
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 458.25
Total Assets 6672.53
Total Liabilities 6672.53
Total Equity 2649.66
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 7.97
Return on Capital (%) 10.98
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 313.29
Total Assets 6063.46
Total Liabilities 6063.46
Total Equity 2114.14
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 10.92
Return on Capital (%) 15.78
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 523.53
Total Assets 6807.39
Total Liabilities 6807.39
Total Equity 2368.01
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 6.14
Return on Capital (%) 9.68
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 163.83
Total Assets 6004.05
Total Liabilities 6004.05
Total Equity 1984.36
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 1.39
Return on Capital (%) 2.2
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 32.12
Total Assets 4756.93
Total Liabilities 4756.93
Total Equity 1935.09
Share Outstanding 181152116
Price to Book Ratio 0.00
Return on Assets (%) 3.38
Return on Capital (%) 4.8
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 141.01
Total Assets 4615.84
Total Liabilities 4615.84
Total Equity 1841.86
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 3.46
Return on Capital (%) 4.56
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 47.88
Total Assets 4323.18
Total Liabilities 4323.18
Total Equity 1712.52
Share Outstanding 180852000
Price to Book Ratio 0.00
Return on Assets (%) 10.33
Return on Capital (%) 13.58
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 260.72
Total Assets 4863.19
Total Liabilities 4863.19
Total Equity 2301.77
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 8.64
Return on Capital (%) 11.66
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 39.21
Total Assets 3871.20
Total Liabilities 3871.20
Total Equity 1914.55
Share Outstanding 180852116
Price to Book Ratio 0.00
Return on Assets (%) 4.52
Return on Capital (%) 5.98
Particulars MAR 2024 (Values in Cr)
Net Income 727.22
Cash from Operations 1320.89
Cash from Investing -712.51
Cash from Financing -164.20
Net change in Cash 220.52
Free Cash Flow 1596.66
Particulars MAR 2023 (Values in Cr)
Net Income 747.21
Cash from Operations 947.32
Cash from Investing -467.68
Cash from Financing -145.39
Net change in Cash 133.77
Free Cash Flow 1337.92
Particulars MAR 2022 (Values in Cr)
Net Income 972.54
Cash from Operations 1079.38
Cash from Investing -788.79
Cash from Financing -151.85
Net change in Cash -172.43
Free Cash Flow 1482.58
Particulars MAR 2021 (Values in Cr)
Net Income 657.32
Cash from Operations 904.86
Cash from Investing -251.84
Cash from Financing -188.90
Net change in Cash 259.06
Free Cash Flow 1050.53
Particulars MAR 2020 (Values in Cr)
Net Income 105.33
Cash from Operations 592.45
Cash from Investing -163.76
Cash from Financing -300.51
Net change in Cash 36.02
Free Cash Flow 747.10
Particulars MAR 2024 (Values in Cr)
Net Income 199.91
Cash from Operations 651.83
Cash from Investing -171.07
Cash from Financing -287.74
Net change in Cash 126.14
Free Cash Flow 901.09
Particulars MAR 2023 (Values in Cr)
Net Income 212.33
Cash from Operations 589.91
Cash from Investing -270.43
Cash from Financing -54.51
Net change in Cash 180.42
Free Cash Flow 861.57
Particulars MAR 2022 (Values in Cr)
Net Income 616.42
Cash from Operations 598.38
Cash from Investing -188.99
Cash from Financing -342.96
Net change in Cash -309.06
Free Cash Flow 772.45
Particulars MAR 2021 (Values in Cr)
Net Income 557.44
Cash from Operations 888.54
Cash from Investing -831.16
Cash from Financing 30.97
Net change in Cash -29.93
Free Cash Flow 988.63
Particulars MAR 2020 (Values in Cr)
Net Income 224.68
Cash from Operations 415.96
Cash from Investing -164.76
Cash from Financing -45.86
Net change in Cash 174.62
Free Cash Flow 516.70
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

EMCURE PHARMACEUTICALS L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1021.90 1.26 redarrow
red-green-graph indicator
13 Bearish
3 Bullish
  • 5 Days 1031.00
  • 26 Days 1023.80
  • 10 Days 1032.10
  • 50 Days 1050.80
  • 12 Days 1030.40
  • 100 Days 1130.40
  • 20 Days 1024.40
  • 200 Days 1278.60
1022.20 PIVOT

First Support

992.90

First Resistance

1038.40

Second Support

976.70

Second Resistance

1067.70

Third Support

947.40

Third Resistance

1083.90

RSI

49.69

ADX

26.56

MACD

6.63

Williams % R

-41.70

Commodity Channel Index (CCI)

0.68

Date

2025-04-30

Week

50570.00

Same Day

14530.00

Month

87609.00

1 Year

1.33

3 Year

1.33

Over 1 Month

-5.03%

down

Over 1 Year

-24.81%

down

Over 3 Months

-16.19%

down

Over 3 Years

0.00%

down

Over 6 Months

-29.20%

down

Over 5 Years

0.00%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

EMCURE PHARMACEUTICALS L shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
15.57%
Promoter Holdings
77.92%
FII
3.06%
DII
3.43%
Promoter Shares(Pledge Percentage)
0.04%
Name Shares Category
Satish R Mehta 7.5396748E7 (39.79%) Shareholding of Promoter and Promoter Group
Bc Investments Iv Limited 1.6439459E7 (8.68%) Public Shareholding
Unity Trust (shares Held By Sunil Rajanikant Mehta With Kamini Sunil Mehta, As Trustees) 1.4508E7 (7.66%) Shareholding of Promoter and Promoter Group
Everest Trust (shares Held By Sanjay Rajanikant Mehta With Sonali Sanjay Mehta, As Trustees) 1.452E7 (7.66%) Shareholding of Promoter and Promoter Group
Samit S Mehta 1.3537632E7 (7.14%) Shareholding of Promoter and Promoter Group
Bhavana Satish Mehta 8916888.0 (4.71%) Shareholding of Promoter and Promoter Group
Namita Vikas Thapar 5071200.0 (2.68%) Shareholding of Promoter and Promoter Group
Pushpa Rajnikant Mehta 3886052.0 (2.05%) Shareholding of Promoter and Promoter Group
Sanjay Rajanikant Mehta 3704028.0 (1.95%) Shareholding of Promoter and Promoter Group
Sunil Rajanikant Mehta 2847012.0 (1.5%) Shareholding of Promoter and Promoter Group
Kamini Sunil Mehta 1664960.0 (0.88%) Shareholding of Promoter and Promoter Group
Niraj Sunil Mehta 1100000.0 (0.58%) Shareholding of Promoter and Promoter Group
Rutav Sunil Mehta 988224.0 (0.52%) Shareholding of Promoter and Promoter Group
Vikas M Thapar 645000.0 (0.34%) Shareholding of Promoter and Promoter Group
Surekha Umakant Shah 318216.0 (0.17%) Shareholding of Promoter and Promoter Group
Suhasinee Saumil Shah 129216.0 (0.07%) Shareholding of Promoter and Promoter Group
Smita Paresh Shah 129216.0 (0.07%) Shareholding of Promoter and Promoter Group
Girish Harrai Desai 115716.0 (0.06%) Shareholding of Promoter and Promoter Group
Shaila Sharad Gujar 77530.0 (0.04%) Shareholding of Promoter and Promoter Group
Swati Hetalkumar Shah 64716.0 (0.03%) Shareholding of Promoter and Promoter Group
Ranjanakumari Mukeshbhai Desai 28928.0 (0.02%) Shareholding of Promoter and Promoter Group
The Ramni And Madan Thapar Revocable Living Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Kaja Investments Llc 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Akanksha Eye Clinic & Nursing Home 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sassy Stories 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Irrevocable Deed Of Trust Of Umakant Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Himalayan Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sapphire Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Menlo Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Cayuga Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Tulsi Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Indus Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
H. M. Sales Corporation 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Heritage Pharma Holdings Inc. 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Thapar Vision Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Incredible Ventures Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Incredible Ideas Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Avet Lifesciences Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Thapar Ventures Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Uth Beverage Factory Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Bhavna Battu 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ramni Thapar 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Madan Mohan Thapar 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Jai Vikas Thapar 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Vir Vikas Thapar 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Aditi Shrivastav 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Malti Bharadwaj 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Akhil Bharadwaj 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shaurya Samit Mehta 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sunidhi Samit Mehta 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Abhilasha Samit Mehta 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Manish J. Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Jigar J. Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pravina J. Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Jashvantlal Hiralal Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shobhna Desai 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

EMCURE PHARMACEUTICALS L corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

EMCURE PHARMACEUTICALS L Share Price

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001.

Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad
range of pharmaceutical products across several major therapeutic areas. They are a research and development driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled to reach target markets across over 70 countries, with a strong presence in India, Europe and Canada. In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

The Company has 13 manufacturing facilities across India. It keeps a strong track record in developing portfolios of differentiated products, including chiral molecules, complex APIs, biologics and novel drug delivery systems. It has a portfolio of 11 chiral molecules, of which 6 have been launched so far.

In year 1999, Lasor Drugs Limited was amalgamated with the Company. Thereafter, Emcure Laboratories Private Limited., Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiraral Mehta Sales Private Limited were amalgamated with Company during the period 2001. The Company established facility in Kurkumbh in 2006 and then started operations of injectables facility in Hinjawadi. The facility established by Company's Subsidiary, Gennova Biopharmaceuticals Limited at
Hinjawadi became operational.

The Company started operations in solid orals at facility in Jammu in 2009. During 2012, it acquired rights of BiCNUr, a branded oncology product prescribed for treatment of brain tumors, multiple myeloma, Hodgkin's disease and non-Hodgkin's lymphoma. Through Subsidiary, Zuventus Healthcare Limited, a manufacturing facility was established in Bengaluru in year 2017 and finally, the Company received licence to work a factory at Sanand, Gujarat in 2018. The subsidiary, Tillomed France S.A.S., was incorporated in France in 2018. The Subsidiary, Emcure Pharma Chile SpA, was incorporated in Chile in 2020.

The Company has a portfolio of six commercialized and in-house manufactured biologics and biologics brands, Elaxim, Tenectase and Hamsyl, each launched into domestic market for the Financial Year 2021. The Company launched biosimilar for Tenecteplase,
commonly used for acute myocardial infraction, and the biosimilar for Pegylated-asparaginase, commonly used for treating patients with leukemia. It hold the global patent for use of Tenectaplase to treat Acute Ischemic Stroke as a second indication in 2021 and Emcure Pharma Philippines Inc., incorporated in Philippines in 2021-22. Tillomed Malta Ltd, was incorporated in Malta in 2022-23.


In July 2024, the Company came up with an Initial Public Offer of issuing 19,375,070 Equity Shares aggregating to Rs 1952.02 Crore comprising a Fresh Issue of 7,946,231 Equity Shares aggregating to Rs 800 Crore and an Offer for Sale of 11,428,839 Equity Shares aggregating to Rs 1152.02 Crore.

Parent organization Indian Private
NSE symbol EMCURE
Founded 1981
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Emcure Pharmaceuticals Ltd?

Answer Field

The share price of Emcure Pharmaceuticals Ltd for NSE is ₹ 1021.9 and for BSE is ₹ 1022.

What is the Market Cap of Emcure Pharmaceuticals Ltd?

Answer Field

The market cap of Emcure Pharmaceuticals Ltd for NSE is ₹ 1,85,11.93 Cr. and for BSE is ₹ 1,85,13.75 Cr. as of now.

What is the 52 Week High and Low of Emcure Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Emcure Pharmaceuticals Ltd for NSE is ₹ 1580.00 and ₹ 889.00 and for BSE is ₹ 1577.50 and ₹ 890.00.

How to Buy Emcure Pharmaceuticals Ltd share?

Answer Field

You can trade in Emcure Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Emcure Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -24.81%.

What is the Current Share Price of Emcure Pharmaceuticals Ltd?

Answer Field

Emcure Pharmaceuticals Ltd share price is for NSE ₹ 1021.9 & for BSE ₹ 1022 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Emcure Pharmaceuticals Ltd Share?

Answer Field

The market cap of Emcure Pharmaceuticals Ltd for NSE ₹ 1,85,11.93 & for BSE ₹ 1,85,13.75 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Emcure Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Emcure Pharmaceuticals Ltd share is 93.74.

What is the PB ratio of Emcure Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Emcure Pharmaceuticals Ltd share is 149.27.

How to Buy Emcure Pharmaceuticals Ltd Share?

Answer Field

You can trade in Emcure Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Emcure Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Emcure Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Emcure Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|